

トロンビン活性化線溶阻止因子 (TAFI) の
正常者血漿中濃度解析

第30回日本血栓止血学会 (2007.11.15-17)

8) 赤津裕康、松本光弘、越智基、谷由章、
Ying Liu、吉田眞理、李野謙次、山本孝之、
堀 映、橋詰良夫

認知症を示した成人型Intranuclear
inclusion body diseaseの一部検例

第35回臨床神経病理懇話会(2007.11.17-18)

9) 堀 映、赤津裕康、谷由章、橋詰良雄
一側眼球摘出後の同側外側膝状体における
transneuronal変性

第35回臨床神経病理懇話会(2007.11.17-18)

I. 知的財産権の出願・登録状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

厚生労働科学研究費補助金（ヒトゲノム・再生医療等研究事業）

（分担）研究報告書

アルツハイマー病発症の危険因子であるコレステロール代謝関連遺伝子の機能解析

分担研究者 藤野貴広 愛媛大学・総合科学研究支援センター 准教授

研究要旨：NSE（Neuron Specific Enolase）プロモーター下流にCYP46A1・myc cDNAを連結したトランスジェニック（Tg）マウスを作製した。得られた26個体のTgマウスの内、5個体のみが脳においてmCYP46A1・mycタンパク質を発現していた。約3ヶ月齢及び6ヶ月齢のTgマウス血清及び脳組織中のコレステロール含量を測定したが、同腹野生型との間に有意な差は見いだせなかった。また、組織解析でも異常は観察されなかった。24-水酸化コレステロールの7位を水酸化するCYP39A1及びCYP7B1・cDNAを単離し、アデノウイルスベクターに組み込んだ。CHO細胞に感染させ、25-水酸化コレステロールを基質として活性を測定したところ、非常に高い発現が観察された。しかし、CYP46A1をCYP39A1又はCYP7B1を同時にCHO細胞に発現させたが、7、24-水酸化コレステロール生成の増加は観察されなかった。脳神経系から余剰なコレステロールの排出においてはCYP46A1による24-水酸化コレステロールの生成段階が律速になっていることを示唆した。

A. 研究目的

脳神経系の脂質代謝は脳血液関門によって体循環系とは隔絶されているため、脳神経系から余剰なコレステロールの排出機構の解明は特に重要である。脳特異的に発現するCYP46A1は脳血液関門を容易に通り返ける24-水酸化コレステロールの生成を触媒し、神経細胞からのコレステロール排出に重要な役割を担っている。一方、アルツハイマー病の危険因子として知られるアポEは神経細胞からのコレステロールの引き抜きにも重要である。本研究では、脳内のコレステロール排出機構の解明を通して、アルツハイマー病の予防と治療の基礎を築くことを目的としている。

B. 研究方法

NSEプロモーター及びSV40イントロン配列下流にCYP46A1・myc cDNAとSV40ポリA付加配列を連結したTgマウス作成用ミニジーンをC57BL/6J・マウス受精卵の前核にマイクロインジェクションすることで作製した。Tgマウスのスクリーニングは特異的プライマーを用いたPCRによって行った。また、脳におけるmCYP46A1・mycタンパク質の検出は抗myc-tag抗体を用いたイムノプロット法で行った。組織中及び血清中のコレステロール濃度はコレステロール測定キットを用い

て定量化した。また、Tgマウスの組織はパラホルムアルデヒド固定・パラフィン包

埋切片を作製し、組織染色及び免疫組織染色に供した。

マウス脳又は肝臓・mRNA を鋳型として RT-PCR 法によりマウス CYP39A1 及び CYP7B1・cDNA を増幅し、更に PCR 法により C 末に HA-tag を挿入した。シーケンスにより配列を確認後、アデノウィルスベクターに組み込み、CHO 細胞に感染させることで、CYP39A1 及び CYP7B1 活性を確認した。

(倫理面への配慮)

実験動物を用いる実験は、愛媛大学医学部動物実験倫理委員会の承認を受けて行われた。

A. 研究結果

NSE (Neuron Specific Enolase) プロモーター下流に CYP46A1・myc cDNA を連結したトランスジェニック (Tg) マウスを作製した。抗 myc-tag 抗体を用いたイムノプロットにより、CYP46A1・myc タンパク質の発現を解析した。26 系統の Tg マウスの内、5 系統で mCYP46A1・myc の発現が認められた。この 5 系統の内、比較的発現が高い 4-1 系統及び 2-3 系統の組織特異性を解析したところ、CYP46A1・myc は脳以外にも肺や心臓で脳と同程度の発現が認められた。この 2 系統において、約 3 ヶ月齢及び 6 ヶ月齢の Tg マウス血清及び脳組織中のコレステロール含量を測定したが、同腹野生型との間に有意な差は見いだせなかった。また、各マウス脳のパラフィン包埋切片を作製し、組織染色及び免疫組織染色に

より解析を行ったが、いずれのマウスでも異常は観察されなかった。

24-水酸化コレステロールの 7 位を水酸化する CYP39A1 及び CYP7B1・cDNA を単離し、HA-tag を付加した後にアデノウィルスベクターに組み込んだ。CHO 細胞に感染させ、抗 HA-tag 抗体を用いたイムノプロットによりタンパク質の発現、25-水酸化コレステロールを基質として活性を測定した。いずれの酵素も、その発現量の増加に伴って酵素活性の増加も観察された。一方、CYP46A1 と共に CYP39A1 又は CYP7B1 を同時に CHO 細胞に発現させた所、24-水酸化コレステロールから 7、24-水酸化コレステロール生成の増加は観察されたものの、コレステロールから 7、24-水酸化コレステロール生成の増加には繋がらなかった。

D. 考察

脳神経系で CYP46A1 を高発現する Tg マウスを作製するために、NSE プロモーター下流に CYP46A1・myc cDNA を組み込んだ。最終的に 5 系統のみが脳において mCYP46A1・myc を発現していた。この発現はイムノプロットによる解析から、それほど高い発現量ではなかった。この結果は、Tg マウス血清及び脳組織中のコレステロール含量や組織染色及び免疫組織染色による解析で、同腹野生型マウスとの間で違いが見られなかった結果と一致する。通常、24-水酸化コレステロールはヒト及びマウス血中ではほとんど検出されない。24-水酸化コレステロールは更に水溶性の高い 7、24-水酸化コレステロールへと素早く変換され、肝臓にお

いて胆汁酸へと代謝されるためである。一方、CYP7B1 欠損患者では血清中の 24-水酸化コレステロールと共に 25-及び 27-水酸化コレステロール値が高くなることが示されている。そこで、24-水酸化コレステロールの 7 位を水酸化し、7、24-水酸化コレステロールを生成する CYP7B1 及び CYP39A1 が、CYP46A1 活性に及ぼす影響を観察するために、これらの cDNA を組み込んだアデノウィルスベクターを構築し、CHO 細胞に感染させた。25-水酸化コレステロールを基質として活性を測定したところ、非常に高い発現が観察された。しかし、CYP46A1 を CYP39A1 又は CYP7B1 を同時に CHO 細胞に発現させたが、7、24-水酸化コレステロール生成の増加は観察されなかった。これらの結果は、脳神経系から余剰なコレステロールの排出においては CYP46A1 による 24-水酸化コレステロールの生成段階が律速になっていることを示唆した。

E. 結論

CYP46A1・myc を脳神経系で発現する Tg マウスを作製した。最終的に 5 系統の Tg マウスのみが脳において mCYP46A1・myc を発現していた。比較的 CYP46A1 の発現が高い 2 系統において、約 3 ヶ月齢及び 6 ヶ月齢の Tg マウス血清及び脳組織中のコレステロール含量を測定したが、同腹野生型との間に有意な差は見いだせなかった。また、組織染色及び免疫組織染色により解析を行ったが、いずれのマウスでも異常は観察されなかった。24-水酸化コレステロールの 7 位を水酸化する CYP39A1 及び CYP7B1・

cDNA を CHO 細胞に導入し、25-水酸化コレステロールを基質として活性を測定した。いずれの酵素も、その発現量の増加に伴って酵素活性の増加も観察された。一方、CYP46A1 と共に CYP39A1 又は CYP7B1 を同時に CHO 細胞に発現させた所、24-水酸化コレステロールから 7、24-水酸化コレステロール生成の増加は観察されたものの、コレステロールから 7、24-水酸化コレステロール生成の増加には繋がらなかった。

F. 健康危険情報

なし

G. 研究発表

1. 論文発表

なし

2. 学会発表

王衆、松田正司、劉明哲、田中ゆき、藤野貴広

中枢神経系に於けるリポタンパク受容体の機能解析

第 62 回 日本解剖学会 中国・四国支部
学術集会

2007 年 10 月 27-28 日、倉敷

Takahiro Fujino, Mingzhe Liu, Zhong

Wang, Yuki Tanaka

**Molecular Characterization of
Xenobiotics Acyl-CoA Synthetases**

International symposium on biological
responses to chemical pollutants

グローバル COE 国際シンポジウム

2008年3月6-7日、松山

藤野貴広、西村豊樹、劉明哲、王衆、田中ゆき、能勢真人

Fraser 症候群様表現型を示す新規変異マウスの解析

日本農芸化学会 2008 年度大会

2008年3月27-29日、名古屋

王衆、松田正司、劉明哲、田中ゆき、藤野貴広

中枢神経系に於けるリポタンパク受容体の機能解析 第113回 日本解剖学会 総会

2007年10月27-28日、大分県由布市

H. 知的財産権の出願・登録状況

特許取得

なし

実用新案登録

なし

III. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

著者名	論文タイトル名	発表誌名	巻号	ページ	出版年
Zou K, Hosono T, Nakamura T, Shiraishi H, Maeda T, Komano H, Yanagisawa K, <u>Michikawa M</u>	Novel role of presenilins in maturation and transport of integrin β 1.	<i>Biochemistry</i>	印刷中	印刷中	2008
Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yanagisawa K, <u>Michikawa M.</u>	Angiotensin-converting enzyme converts amyloid β -protein1-42 ($A\beta(1-42)$) to $A\beta(1-40)$, and its inhibition enhances brain $A\beta$ deposition.	<i>J Neurosci</i>	27(32)	8628-8635	2007
Gong JS, Morita SY, Kobayashi M, Handa T, Fujita SC, Yanagisawa K, <u>Michikawa M.</u>	Novel action of apolipoprotein E (ApoE): ApoE isoform specifically inhibits lipid-particle-mediated cholesterol release from neurons.	<i>Mol Neurodegeneration</i>	2:9	1-9	2007
Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, <u>Michikawa M,</u> Yanagisawa K.	A ganglioside-induced toxic soluble $A\beta$ assembly. Its enhanced formation from $A\beta$ bearing the Arctic mutation.	<i>J Biol Chem.</i>	282(4)	2646-2655	2007
Araki W., Takahashi-Sasaki N., Chui DH., Saito S., Takeda K., Shirota K., Takahashi K., Murayama KS., Kametani F., Shiraishi H.,	A family of membrane proteins associated with presenilin expression and γ -secretase function.	<i>FASEB J</i>	印刷中	印刷中	2007

Komano H., Tabira T.					
Kamei, H., Saito, T., Ozawa, M., Fujita, Y., Asada, A., Bibb, J.A., Saido, T.C., Sorimachi, H., Hisanaga, S.I.	Suppression of calpain-dependent cleavage of the Cdk5 activator p35 to p25 by site-specific phosphorylation.	<i>J Biol Chem</i>	282	1687-1694	2007
道川 誠 柳澤勝彦	コレステロールと Alzheimer 病	医学のあゆみ	220 巻 5 号	439-444	2007
道川 誠	Alzheimer 病と脂 質.	Clinical Neuro- science	25 巻 2 号	162-164	2007
道川 誠	アルツハイマー病とア ポリポ蛋白質 E	実験医学(増 刊)	25 巻 13 号	46-52	2007
道川 誠	コレステロールとアルツ ハイマー病 Cholesterol paradox を紐解くー考察	ファルマシア	9 巻	876-880	2007
道川 誠	Alzheimer 病研究の進 歩と治療戦略	医学のあゆみ	222 巻	333-339	2007
Okamura N, Furumoto S, Funaki Y, Suemoto T, Kato M, Ishikawa Y, Ito S, Akatsu H, Yamamoto T, Sawada T, Arai H, Kudo Y and Yanai K	Binding and safety profile of novel benzoxazole derivative for in vivo imaging of amyloid deposits in Alzheimer's disease	<i>Geriatrics & Gerontology International.</i>	27	393-400	2007
Wei, J. et al.	Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies.	<i>J Biol Chem</i>	282	28904-14	2007
Waragai, M. et al.	Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease	<i>Neurosci Lett</i>	425	18-22	2007
Nakai, M. et al.	Expression of alpha-synuclein, a presynaptic protein implicated in	<i>Biochem Biophys Res Commun</i>	358	104-10	2007

	Parkinson's disease, in erythropoietic lineage.				
Makino, S. et al.	Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism.	<i>Am J Hum Genet</i>	80,	393-406	2007
Kimura, R. et al.	The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.	<i>Hum Mol Genet</i>	16,.	15-23	2007
Kanai, Y., Akatsu, H., Iizuka, H. & Morimoto, C.	Could serum antibody to poly(ADP-ribose) and/or histone H1 be marker for senile dementia of Alzheimer type?	<i>Ann N Y Acad Sci</i>	1109,	338-44	2007
Akatsu, H. et al.	Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.	<i>Microbiol Immunol</i>	51,	507-17	2007

IV. 研究成果の刊行物・別刷

Angiotensin-Converting Enzyme Converts Amyloid β -Protein 1–42 ($A\beta_{1-42}$) to $A\beta_{1-40}$, and Its Inhibition Enhances Brain $A\beta$ Deposition

Kun Zou,^{1,3} Haruyasu Yamaguchi,⁴ Hiroyasu Akatsu,⁵ Takaaki Sakamoto,¹ Mihee Ko,¹ Kazushige Mizoguchi,² Jian-Sheng Gong,¹ Wenxin Yu,¹ Takayuki Yamamoto,⁵ Kenji Kosaka,⁵ Katsuhiko Yanagisawa,¹ and Makoto Michikawa¹

Departments of ¹Alzheimer's Disease Research and ²Geriatric Medicine, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8522, Japan, ³Japan Society for the Promotion of Science, Tokyo 102-8471, Japan, ⁴Gunma University School of Health Sciences, Maebashi 371-8514, Japan, and ⁵Choju Medical Institute, Fukushima Hospital, Toyohashi 441-8124, Japan

The abnormal deposition of the amyloid β -protein ($A\beta$) in the brain appears crucial to the pathogenesis of Alzheimer's disease (AD). Recent studies have suggested that highly amyloidogenic $A\beta_{1-42}$ is a cause of neuronal damage leading to AD pathogenesis and that monomeric $A\beta_{1-40}$ has less neurotoxicity than $A\beta_{1-42}$. We found that mouse and human brain homogenates exhibit an enzyme activity converting $A\beta_{1-42}$ to $A\beta_{1-40}$ and that the major part of this converting activity is mediated by the angiotensin-converting enzyme (ACE). Purified human ACE converts $A\beta_{1-42}$ to $A\beta_{1-40}$ as well as decreases $A\beta_{1-42}/A\beta_{1-40}$ ratio and degrades $A\beta_{1-42}$ and $A\beta_{1-40}$. Importantly, the treatment of Tg2576 mice with an ACE inhibitor, captopril, promotes predominant $A\beta_{1-42}$ deposition in the brain, suggesting that ACE regulates $A\beta_{1-42}/A\beta_{1-40}$ ratio *in vivo* by converting secreted $A\beta_{1-42}$ to $A\beta_{1-40}$ and degrading $A\beta$ s. The upregulation of ACE activity can be a novel therapeutic strategy for AD.

Key words: angiotensin-converting enzyme; ACE; Alzheimer's disease; amyloid β -protein; $A\beta$; $A\beta$ deposition; $A\beta$ degradation; APP transgenic mouse

Introduction

The progressive accumulation and deposition of the amyloid β -protein ($A\beta$) in the brain are early pathologically important features of Alzheimer's disease (AD) (Selkoe, 2004). It has been assumed that insoluble $A\beta$ amyloid is a culprit for inducing the pathological processes of AD, leading to neuronal dysfunction; however, recent studies have shown that not the insoluble form of $A\beta$ but the soluble form of $A\beta$ oligomers is pathogenic (Kirkitadze et al., 2002; Walsh et al., 2002). $A\beta_{1-42}$ is deposited early and selectively in senile plaques, and this deposition is an invariant feature of all forms of AD (Iwatsubo et al., 1994). A high $A\beta_{42}/A\beta_{40}$ ratio is a major determinant for AD development in familial AD with presenilin mutations (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997).

$A\beta$ s ($A\beta_{1-40}$ and $A\beta_{1-42}$) are constantly secreted by many

types of cell and are normally found in body fluids, including CSF. Recently, we have shown that monomeric $A\beta_{1-40}$ has neuroprotective effects against metal-induced oxidative damage and $A\beta_{1-42}$ -induced neuronal death, whereas $A\beta_{1-42}$ is highly amyloidogenic and thus forms oligomers rapidly at very low concentrations, exerting strong neurotoxicity (Zou et al., 2002, 2003). $A\beta_{1-40}$, but not $A\beta_{1-42}$, rescues neurons from β - or γ -secretase inhibitor-induced cell death (Plant et al., 2003). Moreover, the inhibition of the effects of some nonsteroidal anti-inflammatory drugs, which reduce the risk of AD (in 't Veld et al., 2001), directly blocks $A\beta_{1-42}$ generation by changing presenilin conformation and shifting γ -secretase function toward the production of a shorter soluble $A\beta$ (Weggen et al., 2001; Lleo et al., 2004).

A recent study demonstrated that $A\beta_{42}$ is essential for parenchymal and vascular amyloid deposition in mice and that mice expressing a high $A\beta_{1-40}$ level do not develop overt amyloid pathology (McGowan et al., 2005). Both $A\beta_{1-42}$ and $A\beta_{1-40}$ levels were elevated coordinately in late-onset sporadic AD brains (Selkoe, 2004) and non-AD human brains (Morishima-Kawashima et al., 2000); however, insoluble $A\beta_{42}$ level increases exponentially and steeply in an age-dependent manner, accompanied by much smaller increases in $A\beta_{40}$ level (Morishima-Kawashima et al., 2000). Thus, although it is still debatable whether $A\beta_{1-40}$ is nontoxic or neuroprotective, these findings suggest that decreasing neurotoxic $A\beta_{1-42}$ level could be a strategy for developing AD treatments.

We considered that there is a carboxyl peptidase that converts

Received Dec. 23, 2006; revised June 11, 2007; accepted June 29, 2007.

This work was supported by grants from the Ministry of Health, Labor, and Welfare of Japan (Research on Human Genome and Tissue Engineering Grant H17-004), the Program for Promotion of Fundamental Studies in Health of the National Institute of Biomedical Innovation, and Japan Society for the Promotion of Science, and Grant-in-Aid 18023046 for Scientific Research on Priority Areas—Research on Pathomechanisms of Brain Disorders from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Correspondence should be addressed to Dr. Makoto Michikawa, Department of Alzheimer's Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, 36-3 Gengo, Morioka, Obu, Aichi 474-8522, Japan. E-mail: michi@nils.go.jp.

K. Zou's present address: Department of Neuroscience, Faculty of Pharmaceutical Sciences, Iwate Medical University, Yahaba 028-3694, Japan.

DOI:10.1523/JNEUROSCI.1549-07.2007

Copyright © 2007 Society for Neuroscience 0270-6474/07/278628-08\$15.00/0

secreted neurotoxic $A\beta_{1-42}$ to $A\beta_{1-40}$, thus decreasing $A\beta_{42}/A\beta_{40}$ ratio. This notion has led us to experimentally identify an $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting enzyme in the mouse and human brains. Interestingly, we found that the angiotensin-converting enzyme (ACE) is a major $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting enzyme in the brain. This suggests that the modulation of ACE activity can be a novel therapeutic strategy for AD.

Materials and Methods

Captopril treatment of Tg2576 mice and tissue preparation. Male human amyloid precursor protein Swedish mutation (hAPPsw) transgenic Tg2576 mice were purchased from Taconic Farms (Germantown, NY). Mice at 6 months of age were fed with captopril-supplemented diet (0.25 mg/g) or control diet *ad libitum* for 7 or 11 months. There were 6–15 animals in each group. Animals were housed singly in individual cages. There were no significant differences in the amount of feed consumed or in the weight of the mice within or between treatment groups. The average captopril intake per animal was 30 mg/kg of body weight/d. Mice were killed by inhalation of CO_2 , and 0.5 ml of blood was collected from the right atrium for the determination of serum ACE activity. Mice were then transcardially perfused with cold PBS. The left hemisphere of the brain was fixed in 4% buffered paraformaldehyde solution at 4°C for 48 h and incubated in 30% sucrose at 4°C for 48 h for histological processing. The right hemisphere of the brain was separated into the cerebral cortex, hippocampus, thalamus, and brainstem, and these samples were rapidly frozen in liquid nitrogen and stored at $-80^\circ C$ until analysis.

Human postmortem brain tissue. Frontal cortex tissue samples from autopsied control subjects ($n = 15$; male, 9, female, 6; neuropathological diagnosis, physiological aging) and AD subjects ($n = 15$; male, 9, female, 6; clinical and neuropathological diagnosis, AD) were obtained from Fukushima Hospital (Toyohashi, Japan). Tissues were frozen immediately in liquid nitrogen at autopsy and then stored at $-80^\circ C$ until use. The average postmortem delay was 7.7 h and was not significantly different between the two groups. The average age of the subjects of the control group was 84.7 ± 1.9 , and that of the subjects of the AD group was 85.5 ± 1.9 (data represent means \pm SEM; $p = 0.75$, ANOVA, Bonferroni/Dunn test). Experiments using human brains were performed after obtaining the informed consent of the patients' guardians for diagnosis and biochemical, molecular biological, and genomic research. This study was examined and approved by the Ethics Committee of Fukushima Hospital on October 6, 2005, and assigned the application number 180.

ACE activity assay. Cortical tissue (50–100 mg) was homogenized in a fourfold (w/v) volume of ACE homogenization buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 25 μM ZnCl₂, and 0.5% Triton X-100) and centrifuged at 4°C at 10,000 $\times g$ for 15 min. ACE activity in the supernatant against the synthetic substrate *N*-hippuryl-L-histidyl-L-leucine was determined using an ACE colorimetric kit (Buhlmann Laboratories, Schönenbuch, Switzerland). The reaction time was 6 h. ACE activity was then normalized by the initial weight of the brain tissue. For mouse serum ACE activity assay, serum was diluted at 1:2. All samples were measured in triplicate.

Western blot analysis for determining conversion of $A\beta_{1-42}$ to $A\beta_{1-40}$. Somatic ACE-deficient mice (002680) were obtained from The Jackson Laboratory (Bar Harbor, ME). $A\beta_{1-42}$ (Peptide Institute, Osaka, Japan) was freshly dissolved in 0.1% $NH_3 \cdot H_2O$ at 200 μM for each experiment. The wild-type mouse brain cortex, including the hippocampus, was homogenized in a twofold volume (w/v) of a buffer containing 10 mM Tris.HCl, pH 7.5, and 0.15 M NaCl, and the homogenate was centrifuged at 500 $\times g$ for 10 min. The supernatant was mixed with synthetic $A\beta_{1-42}$ to a final concentration of 30 μM and incubated at 37°C for 8 h. Ten microliters of the mixture was subjected to SDS-PAGE and blotted on a nitrocellulose membrane. To enhance the reactivity to an anti- $A\beta_{1-40}$ antibody, the membrane was boiled in PBS for 3 min after blotting, probed with an anti- $A\beta_{1-40}$ monoclonal antibody (1A10) (IBL, Takasaki, Japan), and visualized with SuperSignal (Pierce, Rockford, IL). Because of the high level of exogenous $A\beta_{1-42}$, the membrane was not boiled before the reaction with a polyclonal anti- $A\beta_{1-42}$ antibody.

Thioflavin-T binding assay for aggregated $A\beta$. Determination of the

aggregated state of $A\beta$ was performed on the basis of a previously established method (Levine, 1995, 1999). The incubated $A\beta$ peptides were centrifuged at 17,000 $\times g$ for 60 min, the supernatant was removed, and the precipitate was suspended in 1 ml of 5 μM thioflavin-T in 50 mM glycine-NaOH, pH 8.5. Steady-state fluorescence intensities for each sample were determined as described previously (Zou et al., 2002).

Matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Purified human ACE (2 U/ml) (Millipore, Billerica, MA) was added to 30 μM $A\beta_{1-42}$ dissolved in 0.1% $NH_3 \cdot H_2O$ and incubated at 37°C for 6 h. Captopril (2 mM) was added to stop the digestion, and the sample was frozen in $-80^\circ C$ until use. The sample was subjected to matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) to detect the generation of $A\beta_{1-40}$. The same amount of ACE or $A\beta_{1-42}$ incubated alone under the same conditions as described above was used as control.

Biotinylation of $A\beta_{1-42}$ and determination of $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting activity in human brain. $A\beta_{1-42}$ was biotinylated using a Proton biotin labeling kit (Vector Laboratories, Burlingame, CA). In brief, 0.5 mg of $A\beta_{1-42}$ was dissolved in DMSO and diluted with distilled water to 100 μl . $A\beta_{1-42}$ was biotinylated with a biotin-labeling reagent, and free biotin was removed using gel filtration slurry provided with the kit. The human frontal cortex tissue sample used was from a 76-year-old autopsied non-AD subject. The brain tissue was homogenized in a fourfold volume (w/v) of PBS, and the homogenate was mixed with biotinylated $A\beta_{1-42}$ at a concentration of 0.5 $\mu g/\mu l$. The mixtures were incubated at 37°C for 8 h with or without an ACE inhibitor (1 μM), namely captopril or enalapril. After incubation, 8 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate was added to extract $A\beta$ s. The samples were centrifuged at 4°C and 10,000 $\times g$ for 10 min, and the supernatant was applied to avidin agarose provided with the kit to purify biotinylated $A\beta$ s. Avidin agarose was washed with PBS four times, and biotinylated $A\beta$ s were eluted with 50 mM DTT in SDS-PAGE sample buffer. Biotinylated $A\beta_{1-40}$ converted from biotinylated $A\beta_{1-42}$ was detected by Western blot analysis using an anti- $A\beta_{1-40}$ monoclonal antibody (1A10).

Immunohistochemistry. The left hemispheres of the brains of Tg2576 mice were sagittally cut into 30 μm sections using a freezing microtome (RM 2145; Leica, Wetzlar, Germany). Thioflavin-S staining was performed as described previously (Wyss-Coray et al., 2001). For each mouse, thioflavin-S-positive plaques were counted in four to five sections per left hemisphere of the brain at a magnification of 40 \times . Serial sections were immunostained with anti- $A\beta_{1-40}$ and anti- $A\beta_{1-42}$ end-specific polyclonal antibodies, namely, RIB40 and RIB42, respectively (2 $\mu g/ml$; IBL), after a brief formic acid pretreatment, and immunopositive signals were visualized using an ABC elite kit (Vector Laboratories). Images of the cerebral cortex and hippocampus were captured using a digital camera attached to a microscope and analyzed using simple PCI software (Compix Imaging Systems, Lake Oswego, OR). $A\beta_{1-40}$ and $A\beta_{1-42}$ plaques were estimated as the percentage of immunostained area (positive pixels) divided by the examined area (total pixels). The quantification of thioflavin-S-positive plaques and areas attained by anti- $A\beta_{1-40}$ and anti- $A\beta_{1-42}$ antibodies was performed in a double-blind manner.

$A\beta$ ELISA. Mouse cortices for ELISA were homogenized in 10 volumes of a mixture containing 5.0 M guanidine.HCl and 50 mM Tris.HCl, pH 8.0 (w/v), as described previously (Johnson-Wood et al., 1997). The brain homogenates were further diluted at 1:20 for 13-month-old and 1:500 for 17-month-old mice in a dilution buffer provided with the ELISA kit (Wako, Osaka, Japan). $A\beta_{1-42}$ and $A\beta_{1-40}$ standards (Peptide Institute) were prepared such that the final composition included the same concentration of guanidine. Purified human ACE (2 U/ml) with 10 μM $A\beta_{1-42}$ was diluted at 1:1000 with a dilution buffer containing complete protease inhibitor mixture (Roche, Mannheim, Germany). $A\beta_{1-42}$ and $A\beta_{1-40}$ levels were determined using the ELISA kit. Fibroblasts stably expressing human APP695 (Shiraishi et al., 2004) were grown in DMEM (Invitrogen, Grand Island, NY) containing 10% fetal calf serum. The medium was changed at 100% confluence, and the fibroblasts were treated with or without captopril. The levels of $A\beta_{1-40}$ and $A\beta_{1-42}$ in the medium were determined 24 h after the treatment of fibroblasts with captopril. All samples were measured in triplicate.

Results

We used two specific anti- $A\beta_{1-42}$ and anti- $A\beta_{1-40}$ antibodies to examine $A\beta_{1-40}$ generation in a tissue homogenate mixed with exogenously added synthetic $A\beta_{1-42}$. There was no cross-reaction between the two antibodies, which was confirmed by Western blot analysis (Fig. 1A). The coincubation of $A\beta_{1-42}$ with mouse cerebral homogenate generated $A\beta_{1-40}$, indicating the existence of an $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting enzyme. Also, the generation of $A\beta_{1-40}$ from synthetic $A\beta_{1-42}$ was inhibited by the ACE inhibitors captopril and enalapril (Fig. 1B; supplemental Table 1, available at www.jneurosci.org as supplemental material). This converting activity was also found in the mouse cerebellum, kidney, heart, spleen, lung, skeletal muscle, and serum, indicating that the $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting enzyme is distributed widely. In our Western blot system, neither endogenous $A\beta_{1-40}$ nor $A\beta_{1-42}$ was detected in these samples (data not shown). Moreover, Western blot analysis showed that the brain homogenate and serum from somatic ACE-deficient mice contain a markedly decreased capacity of generating $A\beta_{1-40}$ from $A\beta_{1-42}$ compared with those from wild-type (ACE+/+) and heterozygote (ACE+/-) mice (Fig. 1C). ACE is a dipeptidyl carboxypeptidase that catalyzes the cleavage of C-terminal dipeptides of several substrates and is widely distributed in mammalian tissues. These lines of evidence suggest that ACE in the brain homogenate plays a major role in the conversion of $A\beta_{1-42}$ to $A\beta_{1-40}$.

Thus, we next performed Western blot analysis, ELISA, and MALDI-TOF-MS to examine whether purified human ACE cleaves the 2 aa at the C terminus of synthetic $A\beta_{1-42}$ to generate $A\beta_{1-40}$. After the incubation of $A\beta_{1-42}$ with ACE, $A\beta_{1-40}$ level increased in a time-dependent manner, whereas $A\beta_{1-42}$ level decreased (Fig. 1D, G). Determination of the level of $A\beta_{1-40}$ generated and $A\beta_{1-42}$ remaining in the solution containing synthetic $A\beta_{1-42}$ and ACE shows that the levels of $A\beta_{1-40}$ and $A\beta_{1-42}$ were inversely and significantly correlated (supplemental Fig. 1C, available at www.jneurosci.org as supplemental material). $A\beta_{1-40}$ generation was completely inhibited by ACE inhibitors, namely, EDTA, captopril, and enalapril (Fig. 1D; supplemental Table 2, available at www.jneurosci.org as supplemental material). Because $A\beta_{1-42}$ can easily aggregate in aqueous buffers, it is important to understand whether ACE can mediate the cleavage of the aggregated form of $A\beta_{1-42}$. We performed thioflavin-T assay to monitor $A\beta_{1-42}$ aggregation. The thioflavin-T fluorescence of $A\beta_{1-42}$ incubated with or without ACE or of the mouse brain lysate showed no increase after 8 h of incubation. After 24 h of incubation, the thioflavin-T fluorescence of $A\beta_{1-42}$ incubated alone and with the brain homogenate markedly increased; however, ACE strongly inhibited the increase in thioflavin-T fluorescence (supplemental Fig. 1A, available at www.jneurosci.org as supplemental material). These results suggest that $A\beta_{1-40}$ is converted from nonfibril $A\beta_{1-42}$ within 8 h of incubation. We previously reported that $A\beta_{1-42}$ with random structures transformed to a β -sheet structure after 4 h of incubation at 37°C (Zou et al., 2003). Together with the present finding that the level of $A\beta_{1-40}$ converted from $A\beta_{1-42}$ increased until 8 h of incubation, it is possible that ACE generates $A\beta_{1-40}$ from $A\beta_{1-42}$ with both random and β -sheet structures.

Next we examined whether ACE degrades or converts aggregated $A\beta_{1-42}$. ACE did not reduce the thioflavin-T fluorescence of aggregated $A\beta_{1-42}$ after 24 h of incubation (supplemental Fig. 1B, available at www.jneurosci.org as supplemental material), and no $A\beta_{1-40}$ converted from $A\beta_{1-42}$ was detected by Western




Figure 1. ACE converts $A\beta_{1-42}$ to $A\beta_{1-40}$. **A**, We confirmed the specificities of monoclonal anti- $A\beta_{1-40}$ (1A10) and polydonal anti- $A\beta_{1-42}$ antibodies. One microgram each of $A\beta_{1-40}$ and $A\beta_{1-42}$ was subjected to SDS-PAGE and then blotted onto a nitrocellulose membrane, and the membrane was probed with anti- $A\beta_{1-40}$ and anti- $A\beta_{1-42}$ antibodies. **B**, Mouse brain homogenate was mixed with or without synthetic $A\beta_{1-42}$ and incubated at 37°C for 8 h. An anti- $A\beta_{1-40}$ antibody was used for detecting $A\beta_{1-40}$ generation. Captopril (1 μ M) or enalapril (1 μ M) markedly inhibited the generation of $A\beta_{1-40}$ from $A\beta_{1-42}$. **C**, Top, The genotypes of ACE(+/+), ACE(+/-), and ACE(-/-) mice were confirmed by Western blot analysis of the brain homogenate using an anti-ACE polydonal antibody (AF1513; R & D Systems). Middle, Bottom, Mouse brain homogenate (middle) or serum (bottom) was mixed with 30 μ M $A\beta_{1-42}$ and incubated at 37°C for 8 h. The generation of $A\beta_{1-40}$ was detected by Western blot analysis. **D**, Purified human ACE (2 U/ml) was mixed with synthetic $A\beta_{1-42}$ (30 μ M), and the mixture was incubated at 37°C with or without ACE inhibitors. Top, $A\beta_{1-40}$ was generated in a time-dependent manner. Bottom, EDTA (10 μ M), captopril (1 μ M), and enalapril (1 μ M) completely inhibited the conversion of $A\beta_{1-42}$ to $A\beta_{1-40}$. **E**, MALDI-TOF-MS revealed a new peak with a mass of 4330 (corresponding to that of $A\beta_{1-40}$) after the incubation of $A\beta_{1-42}$ with ACE, indicating $A\beta_{1-40}$ generation. **F**, Captopril blocked $A\beta_{1-40}$ generation in the mixture of $A\beta_{1-42}$ and purified human ACE in a dose-dependent manner. The density of $A\beta_{1-40}$ bands was measured by densitometry and normalized to the mean of the bands in the case of incubation without captopril. IC_{50} was estimated to be \sim 10 nM. **G**, Time-dependent alterations in $A\beta_{1-42}$ and $A\beta_{1-40}$ levels in the solution of $A\beta_{1-42}$ (10 μ M) alone; $A\beta_{1-42}$ (10 μ M) and ACE (2 U/ml); or $A\beta_{1-42}$ (10 μ M), ACE (2 U/ml), and captopril (1 μ M). Each solution was incubated at 37°C for the time indicated. Ten microliters of each solution were collected at different time points and immediately frozen at -80°C until analysis. The levels of $A\beta_{1-42}$ and $A\beta_{1-40}$ in each sample were determined by ELISA. Data are the mean \pm SEM of three samples.

Table 1. Kinetic parameters for conversion of $A\beta_{1-42}$ to $A\beta_{1-40}$ by human kidney ACE

Substrate	Product	K_m (μM)	k_{cat} (s^{-1})	k_{cat}/K_m ($\text{s}^{-1}\cdot\text{mM}^{-1}$)
$A\beta_{1-42}$	$A\beta_{1-40}$	7	4.2	600

$A\beta_{1-42}$ peptides (0, 2.5, 5, 10, 15, 20, 25, 30, and 50 μM) were incubated at 37°C for 8 h with human kidney ACE (0.45 μM). The level of $A\beta_{1-40}$ was determined by ELISA, and K_m , k_{cat} , and k_{cat}/K_m were then calculated.

blot analysis (data not shown), suggesting that ACE cannot degrade aggregated $A\beta_{1-42}$ or convert aggregated $A\beta_{1-42}$ to $A\beta_{1-40}$. MALDI-TOF-MS demonstrated peaks with molecular masses of 4330 and 4514 after incubation for 8 h, which matched the predicted masses of $A\beta_{1-40}$ and $A\beta_{1-42}$, respectively (Fig. 1E). MALDI-TOF-MS of the reaction mixture of ACE and $A\beta_{1-42}$ revealed several peaks with masses corresponding to those of $A\beta_{1-35}$, $A\beta_{1-34}$, $A\beta_{1-22}$, $A\beta_{1-20}$, and $A\beta_{1-19}$, in addition to $A\beta_{1-40}$. Interestingly, however, no $A\beta_{1-38}$, $A\beta_{1-7}$, or $A\beta_{8-42}$ was detected by our MALDI-TOF-MS. No $A\beta_{1-40}$ was detected by MALDI-TOF-MS in a solution of purified ACE or synthetic $A\beta_{1-42}$ after incubation at 37°C (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). The IC_{50} of captopril needed for purified human ACE to convert $A\beta_{1-42}$ to $A\beta_{1-40}$ was ~ 10 nM, indicating the specific inhibitory effect of captopril on ACE-mediated $A\beta_{1-42}$ -to- $A\beta_{1-40}$ conversion (Fig. 1E).

Next we determined the level of $A\beta_{1-40}$ converted from $A\beta_{1-42}$ and that of $A\beta_{1-42}$ remaining in the mixture of $A\beta_{1-42}$ and ACE using an ELISA kit. To determine the level of $A\beta_{1-42}$ lost from the solutions as a result of the “sticky” nature of $A\beta_{1-42}$, we also determined $A\beta_{1-42}$ level in the absence or presence of ACE with an ACE inhibitor as control. During the incubation of $A\beta_{1-42}$ with ACE for 2–8 h, ~ 10 –20% of the degraded $A\beta_{1-42}$ was converted to $A\beta_{1-40}$. These results indicate that $A\beta_{1-40}$ can be generated from $A\beta_{1-42}$ through the action of ACE and that ACE cleaves $A\beta_{1-42}$ at other sites as well (Fig. 1F), which are supported by the results of MALDI-TOF-MS. Moreover, $A\beta_{40}/A\beta_{42}$ ratio increased during the incubation period, suggesting that ACE decreases $A\beta_{42}/A\beta_{40}$ ratio via its $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting activity (data not shown). To understand the catalytic efficiency of ACE converting $A\beta_{1-42}$ to $A\beta_{1-40}$, we performed a kinetic assay of this conversion. The K_m , k_{cat} , and k_{cat}/K_m of the $A\beta_{1-42}$ -to- $A\beta_{1-40}$ conversion by ACE were determined to be 7 μM , 4.2 s^{-1} , and 600 $\text{s}^{-1}\cdot\text{mM}^{-1}$, respectively (Table 1). These values were similar to those of ACE for angiotensin I (Ang I) hydrolysis (Hayakari et al., 2003). Thus, this $A\beta_{1-42}$ -to- $A\beta_{1-40}$ conversion activity of ACE is likely favorable *in vivo* under normal physiological conditions.

To determine whether the human brain shows this $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting activity and whether the activity is inhibited by ACE inhibitors, we used the frontal cortex from a 76-year-old non-AD subject. To exclude the effect of endogenous $A\beta_{1-40}$, we labeled synthetic $A\beta_{1-42}$ with biotin. The sites of biotinylation were at lysine residues amino acid positions 16 and 28 in $A\beta_{1-42}$. The biotinylated $A\beta$ s were purified with avidin agarose, and biotinylated $A\beta_{1-40}$ generated from biotinylated $A\beta_{1-42}$ was detected by Western blot analysis. Similar to the results for the mouse brain homogenate, the incubation of $A\beta_{1-42}$ with the human brain homogenate resulted in the generation of $A\beta_{1-40}$, and this generation was inhibited by an ACE inhibitor, namely captopril or enalapril (Fig. 2A; supplemental Table 3, available at www.jneurosci.org as supplemental material). No endogenous $A\beta_{1-40}$ was detected in the human brain homogenate that was incubated without biotinylated $A\beta_{1-42}$ (Fig. 2A). These results indicate that the human brain also shows $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -




Figure 2. The human brain shows $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting activity, and this ACE activity decreases in AD brain. **A**, The frontal cortex from a non-AD subject was homogenized in PBS. Biotinylated $A\beta_{1-42}$ was added to the resulting homogenate, and the mixture was incubated at 37°C for 8 h with or without 1 μM ACE inhibitor, namely captopril or enalapril. Biotinylated $A\beta$ s were then purified using avidin agarose, and the conversion of $A\beta_{1-42}$ to $A\beta_{1-40}$ was detected by Western blot analysis using an anti- $A\beta_{1-40}$ monoclonal antibody (1A10) and an anti- $A\beta_{1-42}$ polyclonal antibody. **B**, The cortices from the frontal gyri of the non-AD subjects and AD patients were homogenized in a lysis buffer. The resulting homogenate was centrifuged, and ACE activity in the supernatant was determined using an ACE colorimetric kit. The ACE activities of 15 non-AD control individuals (Cont) and 15 AD patients were measured. **C**, The ACE expression level in the frontal cortex of those 30 subjects was determined by Western blot analysis, and a representative image is shown. Twenty micrograms of protein from the brain homogenate were subjected to SDS-PAGE and Western blot analysis. The membrane was probed with an anti-ACE polyclonal antibody. **D**, The relative densities of the ACE bands were determined by densitometry. AD cases exhibited a significantly decreased ACE expression level. Data are the mean \pm SEM of 15 samples. * $p < 0.05$ versus non-AD control by Mann–Whitney U test.

converting activity and that this activity is mainly mediated by ACE. To determine whether ACE activity and ACE expression level are altered in AD brains, we measured ACE activity and determined ACE expression level by Western blot analysis. AD brains showed reduced ACE activity and expression level compared with age-matched non-AD brains (Fig. 2B–D).

To determine whether ACE inhibition promotes AD pathology, we administered captopril, a blood–brain barrier-penetrating ACE inhibitor, to an AD mouse model (hAPPsw, Tg2576) (Hsiao et al., 1996) and assessed its effect on brain amyloid deposition. Tg2576 mice were fed with a captopril-supplemented diet (captopril, 30 mg/kg of body weight/d) from 6 months of age. The mice were killed at 13 and 17 months of age, and their brains were analyzed. In the 13-month-old mice, captopril treatment resulted in a trend toward an increase in the number of thioflavin-S-positive plaques ($n = 6$ per group; control neocortex, 27.9 ± 6.3 ; neocortex of captopril-treated mice, 34.9 ± 7.3 ; $p = 0.8728$; control hippocampus, 11.3 ± 3.2 ; hip-

pocampus of captopril-treated mice, 21.3 ± 5.8 ; $p = 0.2623$, Mann–Whitney U test). Interestingly, the ELISA of A β s demonstrated a significantly higher $A\beta_{1-42}$ level in the neocortex of the 13-month-old captopril-treated mice than in that of the control mice (control, 504.6 ± 14.1 pmol/g; captopril-treated mice, 643.7 ± 49.0 pmol/g; $p = 0.0374$); however, the level of $A\beta_{1-40}$ remained unchanged (control, 1690.2 ± 141.4 pmol/g; captopril-treated mice, 1700.0 ± 249.8 pmol/g; $p = 0.9361$, Mann–Whitney U test). These results suggest that captopril treatment enhances $A\beta_{1-42}$ deposition to a greater extent than $A\beta_{1-40}$ deposition in the brain.

The analysis of the 17-month-old captopril-treated mice showed 2.5-fold and twofold increases in the number of thioflavin-S-positive plaques in the cortex and hippocampus, respectively, compared with that of the control mice (Fig. 3B,G). Moreover, $A\beta_{1-42}$ -immunopositive areas in the neocortex and hippocampus were respectively 2.6-fold and twofold larger in the 17-month-old captopril-treated mice than in the control mice (Fig. 3A,C,H). Captopril treatment resulted in an increase in $A\beta_{1-40}$ -immunopositive area; however, the increase was not statistically significant (Fig. 3A,D,I). These histological findings are supported by ELISA results. $A\beta_{1-42}$ level increased significantly higher (1.6-fold higher) in the neocortex of the captopril-treated mice than in that of the control mice, whereas $A\beta_{1-40}$ level showed no significant increase in the neocortex of the captopril-treated mice (Fig. 3E,F). Consistent with a previous study (Kawarabayashi et al., 2001), the present study also showed that small “diffuse plaques” appear to be labeled preferentially by the anti- $A\beta_{1-42}$ antibody, whereas big “cored plaques” are labeled by the anti- $A\beta_{1-40}$ antibody (Fig. 3A). Captopril treatment decreased serum ACE activity by 40% and neocortex ACE activity by 26% in the 17-month-old captopril-treated Tg2576 mice compared with that in the control mice (Fig. 3J,K). The activity of brain ACE significantly and inversely correlated with enhanced thioflavin-S-positive plaque formation in the neocortex of the mice (Fig. 3L). These findings indicate that ACE inhibition promotes a greater degree of and earlier $A\beta_{1-42}$ deposition than $A\beta_{1-40}$ deposition, suggesting that a low ACE activity in the brain promotes AD development by enhancing $A\beta_{1-42}$ deposition.

To determine whether acute ACE inhibition has a direct effect on the levels of brain A β s, we treated Tg2576 mice with captopril by one-shot oral gavage. The Tg2576 mice used for this experiment were 9 months of age, younger than those used for chronic treatment and supposed to have few A β deposits. The one-shot oral gavage of captopril (30 mg/kg of body weight in a volume of 150 μ l) to Tg2576 mice resulted in a significant decrease in serum ACE activity (control, 248 ± 21 U/L; captopril-treated mice, 43 ± 2 U/L; $p < 0.01$, Mann–Whitney U test; $n = 6$ each group). The ACE activity in the neocortex of the captopril-treated mice was significantly lower than that of the control mice (control, 38 ± 4 mU/L; captopril-treated, 32 ± 5 mU/L; Mann–Whitney U test, $p < 0.05$; $n = 6$ each group). However, the acute ACE inhibition resulted in no significant increase in the level of $A\beta_{1-42}$ (control, 391 ± 99 pmol/g; captopril-treated mice, 619 ± 94 pmol/g; $p = 0.15$, Mann–Whitney U test; $n = 6$ each group) or $A\beta_{1-40}$ (control, 929 ± 164 pmol/g; captopril-treated mice, 1270 ± 156 pmol/g; $p = 0.20$, Mann–Whitney U test; $n = 6$ each group) in the Tg2576 mouse brain. These results suggest that ACE inhibition does not significantly alter brain A β degradation in the acute phase.

To exclude the possibility that captopril affects γ -secretase processing, thereby altering $A\beta_{42}/A\beta_{40}$ ratio, we treated fibroblasts stably expressing hAPP695 with captopril and quantified

the secreted $A\beta_{1-40}$ and $A\beta_{1-42}$. No cellular ACE in this cell line was detected by Western blot analysis using several anti-ACE antibodies [MAB3500 and MAB3502 (Millipore); ACENabm-9B9 (RDI, Flanders, NJ); 2E2 (Serotec, Oxford, UK); 19501 (QED Bioscience, San Diego, CA); AF1513 (R & D Systems, Minneapolis, MN)] (Fig. 4A) (data not shown). No ACE activity was detected in this cell line either (Fig. 4B). We used a mouse kidney homogenate as a positive control. ACE and ACE activity in the kidney homogenate were clearly detected, and ACE activity was inhibited by captopril (Fig. 4A,B). The treatment with captopril did not alter $A\beta_{1-40}$ or $A\beta_{1-42}$ level or $A\beta_{42}/A\beta_{40}$ ratio in fibroblasts, indicating that captopril has no effect on γ -secretase activity in terms of the shift from $A\beta_{1-42}$ secretion to $A\beta_{1-40}$ secretion (Figs. 4C,D). These results suggest that the enhanced predominant $A\beta_{1-42}$ deposition in the captopril-treated Tg2576 mice is caused by the inhibition of ACE-mediated $A\beta_{1-42}$ -to- $A\beta_{1-40}$ -converting activity and $A\beta_{1-42}$ and $A\beta_{1-40}$ degradations, and not by altering γ -secretase processing.

Discussion

Here, we reported for the first time that ACE converts $A\beta_{1-42}$ to $A\beta_{1-40}$ and that a chronic inhibition of ACE enhances predominant $A\beta_{1-42}$ deposition *in vivo*. A high $A\beta_{1-42}$ level or a high $A\beta_{42}/A\beta_{40}$ ratio appears crucial in AD pathogenesis. Although their molecular mechanisms are not yet fully understood, $A\beta_{1-40}$ and $A\beta_{1-42}$ generations are supposed to be modulated by the shift of γ -cleavage (Weggen et al., 2001; De Strooper, 2003; Lleo et al., 2004). In addition to the γ -cleavage shift theory, $A\beta_{1-40}$ and $A\beta_{1-42}$ have recently been suggested to be generated from a longer form of A β species generated by ϵ -cleavage at every three residues in its carboxyl portion; however, the enzyme involved in carboxypeptidyl cleavage has not yet been identified (Qitakahara et al., 2005). Our present study showed a novel catabolism pathway for modulating $A\beta_{1-42}$ degradation; that is, ACE generates $A\beta_{1-40}$ from secreted $A\beta_{1-42}$ by carboxydipeptidyl cleavage in the mouse and human brains.

ACE is a zinc metallopeptidase and a dipeptidyl carboxypeptidase that cleaves 2 aa from the C terminus of Ang I and converts Ang I to the vasoactive and aldosterone-stimulating peptide Ang II (Corvol et al., 1995). ACE is a membrane-bound enzyme in endothelial cells and several types of epithelial and neuroepithelial cells. The active site of ACE is located in the extracellular space, and the unbound form of ACE circulating in biological fluids, such as plasma and CSF, and both types of ACE have enzymatic activity (Zubenko et al., 1985; Rigat et al., 1990; Sibony et al., 1993). These lines of evidence support our findings that ACE converts $A\beta_{1-42}$ to $A\beta_{1-40}$ and degrades A β s under physiological conditions, thereby contributing to the prevention of A β deposition in the brain. In this study, ~10–20% of degraded $A\beta_{1-42}$ was converted to $A\beta_{1-40}$ in the presence of ACE.

Previous studies showed that the major cleavage site of $A\beta_{1-40}$ is between amino acid positions 7 and 8 (Hu et al., 2001; Oba et al., 2005). If the $A\beta_{1-40}$ generated from $A\beta_{1-42}$ was subsequently cleaved between amino positions 7 and 8 by ACE, then $A\beta_{8-40}$ could have been detected by MALDI-TOF-MS. However, no generation of $A\beta_{1-7}$, $A\beta_{8-40}$, or $A\beta_{8-42}$ in the reaction mixture of ACE and $A\beta_{1-42}$ was detected by MALDI-TOF-MS, indicating that no cleavage between amino positions 7 and 8 occurs in our system. What causes this discrepancy remains undetermined. It is possible that $A\beta_{1-42}$ and $A\beta_{1-40}$ have different conformations, which may allow ACE to access these species differently. Another explanation may be that the ACE used in this study contained the plasma membrane domain from the human kidney, and that




Figure 3. Long-term inhibition of ACE activity enhances $A\beta_{1-42}$ deposition in the 17-month-old hAPPsw transgenic mouse (Tg2576) brain. Tg2576 mice at 6 months of age were treated with captopril (30 mg/kg of body weight/d) and killed after 11 months of treatment. **A**, Sagittal brain sections of 17-month-old control diet-fed and captopril-supplemented diet-fed mice were stained with antibodies specific for $A\beta_{1-42}$ and $A\beta_{1-40}$ to detect human $A\beta$ deposition. Representative images of hippocampi and neocortices with or without treatment are shown. The left four panels are images immunostained by the anti- $A\beta_{1-42}$ antibody, and the right four panels are images of brain sections immunostained by the anti- $A\beta_{1-40}$ antibody. Scale bar, 500 μ m. **B–I**, Determinations of the number of thioflavin-S-positive plaques (**B**, **G**) and immunopositive area demonstrated by anti- $A\beta_{1-42}$ antibody (**C**, **H**) and anti- $A\beta_{1-40}$ antibody (**D**, **I**) in brain neocortex (**B–D**) and hippocampus [**G–I**; $n = 15$ for control diet (Cont; open circles); $n = 11$ for captopril diet (Capt; filled circles)]. **E**, **F**, $A\beta_{1-42}$ (**E**) and $A\beta_{1-40}$ (**F**) levels determined by ELISA in brain neocortex of 17-month-old mice fed with control and captopril-supplemented diets. The ELISA data included both soluble and insoluble $A\beta$ s. **J**, **K**, Serum (**J**) and neocortex (**K**) ACE activities in mice fed with control diet and captopril-supplemented diet. **L**, Significant inverse correlation between ACE activity and the number of thioflavin-S-positive plaques in neocortex. Data are the mean \pm SEM; p was determined by the Mann–Whitney U test (**B–K**) and Spearman rank test (**L**). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.




Figure 4. Effect of captopril on $A\beta_{1-42}/A\beta_{1-40}$ ratio in hAPP-expressing fibroblasts. *A*, Fibroblast homogenate and wild-type mouse kidney homogenate ($40 \mu\text{g}$ of protein) were subjected to Western blot analysis using an anti-ACE polyclonal antibody. No cellular ACE in fibroblasts was detected, whereas ACE in the mouse kidney homogenate as a positive control was clearly detected. *B*, ACE activities in the fibroblast and kidney homogenates were determined. ACE activity in the fibroblast homogenate was very low, whereas that in kidney homogenate was detectable, which was clearly inhibited by captopril ($1 \mu\text{M}$) treatment (filled bars, no captopril; open bars, captopril). *C*, Fibroblasts stably expressing human APP695 were grown in DMEM containing 10% FBS. The cells were treated with or without captopril at 100% confluence after changing the culture medium. The $A\beta_{1-40}$ and $A\beta_{1-42}$ levels in the medium were determined by ELSA after 24 h. Filled bars, $A\beta_{1-40}$; open bars, $A\beta_{1-42}$. *D*, $A\beta_{42}/A\beta_{40}$ ratio was calculated. *C, D*, Note that captopril did not alter the levels of secreted $A\beta$ s (*C*) or $A\beta_{42}/A\beta_{40}$ ratio (*D*).

used in previous studies was the secreted form of ACE in human seminal plasma or Cos7-secreted conditioned media. Additional studies are required to clarify this. In this study, MALDI-TOF-MS demonstrated a peak corresponding to $A\beta_{1-40}$ in the reaction mixture of ACE and $A\beta_{1-42}$ but no peak corresponding to $A\beta_{1-38}$. This suggests that ACE does not cleave the 2 C-terminal amino acids of $A\beta_{1-40}$.

In addition, one may question why $A\beta_{1-40}$ level increases if $A\beta_{1-40}$ can be digested further. It is possible that the most predominant substrate at the start of the reaction is $A\beta_{1-42}$ and that the degradation of $A\beta_{1-40}$ is negligible because the level of $A\beta_{1-40}$ generated from $A\beta_{1-42}$ is extremely low (Fig. 1*F*).

To understand the role of ACE *in vivo*, we induced a chronic ACE inhibition in Tg2576 mice and found that the ACE inhibition enhances $A\beta$ deposition *in vivo*. However, it is important to determine whether acute and short-term treatment with capto-

pril also increases brain soluble $A\beta$ level. To exclude the effect of $A\beta$ deposition, we used younger Tg2576 mice, whose brain shows almost no $A\beta$ deposition (Kawarabayashi et al., 2001), in this experiment. An acute, one-shot oral administration of captopril to the young Tg2576 mice resulted in a significant decrease in serum and brain ACE activities; however, the level of brain $A\beta_{1-42}$ or $A\beta_{1-40}$ was not significantly affected. A recent *in vivo* study also shows that ACE inhibitors at doses similar to those used clinically do not increase the levels of brain $A\beta$ s (Eckman et al., 2006). Previous studies using purified human seminal plasma ACE and cultured cells showed that ACE degrades $A\beta$ s and ACE inhibition increases $A\beta$ levels in APP- and ACE-transfected cells (Hu et al., 2001; Hemming and Selkoe, 2005; Oba et al., 2005). However, these findings seem to disagree with those of *in vivo* studies. One explanation may be that other $A\beta$ -degrading enzymes, such as neprilysin, the insulin-degrading enzyme, and the endothelin-converting enzyme may compensate for the acute reduction in ACE activity *in vivo*. An important issue to be stressed is that even a high captopril dose induces only a slight decrease in brain ACE activity; however, long-term captopril treatment induces a marked and significant enhancement of $A\beta$ deposition in the aged mouse brain. Thus, additional studies are required to determine the chronic effect of ACE inhibitors at clinical doses on AD pathology and development.

Numerous studies have shown that the I allele of ACE *D/I* polymorphism is associated with an increased risk of late-onset AD (Hu et al., 1999; Kehoe et al., 1999; Elkins et al., 2004; Lehmann et al., 2005) and that I polymorphism is associated with a decreased serum ACE level (Rigat et al., 1990). ACE activity in CSF from patients with a moderately severe senile dementia of the AD type has been shown to decrease to 41% of that in CSF from non-AD patients (Zubenko et al., 1985). Because ACE inhibitors are widely used in patients with hypertension, which is a risk factor for AD, it is important to determine the effects of ACE inhibitors on $A\beta$ deposition *in vivo*. We have treated an AD mouse model (hAPP^{sw}, Tg2576) (Hsiao et al., 1996) with captopril, a blood–brain barrier-penetrating ACE inhibitor, and found that, consistent with our *in vitro* findings, treatment with captopril enhances the depositions of $A\beta_{1-42}$ and $A\beta_{1-40}$, but more prominently that of $A\beta_{1-42}$ in mouse brains. This suggests that a certain amount of $A\beta_{1-40}$ is generated by ACE from secreted $A\beta_{1-42}$ and that treatment with ACE inhibitors may be a risk factor for AD. There have been very few clinical studies analyzing the effects of ACE inhibitors on AD development and cognitive decline in AD patients, and results to date are inconclusive (Birkenhager et al., 2004; Gard and Rusted, 2004; Ohruu et al., 2004; Khachaturian et al., 2006). Therefore, additional studies are required to determine the effects of ACE inhibitors both on $A\beta$ deposition in the brain of patients during long-term medication with ACE inhibitors and on the cognitive ability of AD patients without hypertension. Together, the results of this study suggest that the upregulation of ACE activity may decrease $A\beta_{42}/A\beta_{40}$ ratio and the levels of $A\beta$ s and can be used as a strategy for developing novel therapeutic regimens for AD patients without hypertension.

References

- Birkenhager WH, Forette F, Staessen JA (2004) Dementia and antihypertensive treatment. *Curr Opin Nephrol Hypertens* 13:225–230.
- Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate $A\beta_{1-42}/1-40$ ratio in vitro and in vivo. *Neuron* 17:1005–1013.

- Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β -protein in both transfected cells and transgenic mice. *Nat Med* 3:67–72.
- Corvol P, Williams TA, Soubrier F (1995) Peptidyl dipeptidase A: angiotensin I-converting enzyme. *Methods Enzymol* 248:283–305.
- De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with presenilin generate an active γ -secretase complex. *Neuron* 38:9–12.
- Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1. *Nature* 383:710–713.
- Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB (2006) Regulation of steady-state β -amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. *J Biol Chem* 281:30471–30478.
- Elkins JS, Douglas VC, Johnston SC (2004) Alzheimer disease risk and genetic variation in ACE: a meta-analysis. *Neurology* 62:363–368.
- Gard PR, Rusted JM (2004) Angiotensin and Alzheimer's disease: therapeutic prospects. *Expert Rev Neurother* 4:87–96.
- Hayakari M, Satoh K, Izumi H, Kudoh T, Asano J, Yamazaki T, Tsuchida S (2003) Kinetic-controlled hydrolysis of Leu-Val-Val-hemorphin-7 catalyzed by angiotensin-converting enzyme from rat brain. *Peptides* 24:1075–1082.
- Hemming ML, Selkoe DJ (2005) Amyloid β -protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. *J Biol Chem* 280:37644–37650.
- Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice. *Science* 274:99–102.
- Hu J, Miyatake F, Aizu Y, Nakagawa H, Nakamura S, Tamaoka A, Takahashi R, Urakami K, Shoji M (1999) Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population. *Neurosci Lett* 277:65–67.
- Hu J, Igarashi A, Kamata M, Nakagawa H (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid β -peptide (A β); retards A β aggregation, deposition, fibril formation; and inhibits cytotoxicity. *J Biol Chem* 276:47863–47868.
- in 't Veld BA, Ruitenbergh A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. *N Engl J Med* 345:1515–1521.
- Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: evidence that an initially deposited species is A β 42(43). *Neuron* 13:45–53.
- Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease. *Proc Natl Acad Sci USA* 94:1550–1555.
- Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid β -protein in the Tg2576 transgenic mouse model of Alzheimer's disease. *J Neurosci* 21:372–381.
- Kehoe PG, Russ C, McClory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, et al. (1999) Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. *Nat Genet* 21:71–72.
- Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC (2006) Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. *Arch Neurol* 63:686–692.
- Kirkpatrick MD, Bitan G, Teplow DB (2002) Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. *J Neurosci Res* 69:567–577.
- Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG (2005) Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. *Am J Epidemiol* 162:305–317.
- Levine III H (1995) Soluble multimeric Alzheimer β (1–40) pre-amyloid complexes in dilute solution. *Neurobiol Aging* 16:755–764.
- Levine III H (1999) Quantification of β -sheet amyloid fibril structures with thioflavin T. *Methods Enzymol* 309:274–284.
- Leo A, Berezovska O, Herl L, Raju S, Deng A, Bacskaï BJ, Frosch MP, Irizarry M, Hyman BT (2004) Nonsteroidal anti-inflammatory drugs lower A β 42 and change presenilin 1 conformation. *Nat Med* 10:1065–1066.
- McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) A β 42 is essential for parenchymal and vascular amyloid deposition in mice. *Neuron* 47:191–199.
- Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi H, Yoshimura M, Sugihara S, Ihara Y (2000) Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid β -protein accumulation in the human brain. *Am J Pathol* 157:2093–2099.
- Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H (2005) The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid β -peptide. *Eur J Neurosci* 21:733–740.
- Ohru T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H (2004) Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. *Neurology* 63:1324–1325.
- Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA (2003) The production of amyloid β -peptide is a critical requirement for the viability of central neurons. *J Neurosci* 23:5531–5535.
- Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotsu N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y (2005) Longer forms of amyloid β -protein: implications for the mechanism of intramembrane cleavage by γ -secretase. *J Neurosci* 25:436–445.
- Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 86:1343–1346.
- Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, et al. (1996) Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med* 2:864–870.
- Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. *Nat Cell Biol* 6:1054–1061.
- Shiraishi H, Sai X, Wang HQ, Maeda Y, Kurono Y, Nishimura M, Yanagisawa K, Komano H (2004) PEN-2 enhances γ -cleavage after presenilin heterodimer formation. *J Neurochem* 90:1402–1413.
- Sibony M, Gasc JM, Soubrier F, Alhenc-Gelas F, Corvol P (1993) Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme. *Hypertension* 21:827–835.
- Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid β -protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416:535–539.
- Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity. *Nature* 414:212–216.
- Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L (2001) TGF- β 1 promotes microglial amyloid- β clearance and reduces plaque burden in transgenic mice. *Nat Med* 7:612–618.
- Zou K, Gong JS, Yanagisawa K, Michikawa M (2002) A novel function of monomeric amyloid β -protein serving as an antioxidant molecule against metal-induced oxidative damage. *J Neurosci* 22:4833–4841.
- Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M (2003) Amyloid β -protein (A β)1–40 protects neurons from damage induced by A β 1–42 in culture and in rat brain. *J Neurochem* 87:609–619.
- Zubenko GS, Volicer L, Drenfeld LK, Freeman M, Langlais PJ, Nixon RA (1985) Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy. *Brain Res* 328:215–221.

A Ganglioside-induced Toxic Soluble A β Assembly ITS ENHANCED FORMATION FROM A β BEARING THE ARCTIC MUTATION*

Received for publication, June 29, 2006, and in revised form, November 27, 2006. Published, JBC Papers in Press, November 29, 2006, DOI 10.1074/jbc.M606202200

Naoki Yamamoto^{†§}, Etsuro Matsubara[‡], Sumihiro Maeda[¶], Hirohisa Minagawa[‡], Akihiko Takashima[¶],
Wakako Maruyama^{||}, Makoto Michikawa[‡], and Katsuhiko Yanagisawa^{†1}

From the Departments of [†]Alzheimer's Disease Research and ^{||}Geriatric Medicine, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Obu 474-8522, Japan, the [‡]Japan Society for the Promotion of Sciences, Tokyo 102-8472, Japan, and the [¶]Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, Wako 351-0198, Japan

The mechanism underlying plaque-independent neuronal death in Alzheimer disease (AD), which is probably responsible for early cognitive decline in AD patients, remains unclarified. Here, we show that a toxic soluble A β assembly (TA β) is formed in the presence of liposomes containing GM1 ganglioside more rapidly and to a greater extent from a hereditary variant-type ("Arctic") A β than from wild-type A β . TA β is also formed from soluble A β through incubation with natural neuronal membranes prepared from aged mouse brains in a GM1 ganglioside-dependent manner. An oligomer-specific antibody (anti-Oligo) significantly suppresses TA β toxicity. Biophysical and structural analyses by atomic force microscopy and size exclusion chromatography revealed that TA β is spherical with diameters of 10–20 nm and molecular masses of 200–300 kDa. TA β induces neuronal death, which is abrogated by the small interfering RNA-mediated knockdown of nerve growth factor receptors, including TrkA and p75 neurotrophin receptor. Our results suggest that soluble A β assemblies, such as TA β , can cause plaque-independent neuronal death that favorably occurs in nerve growth factor-dependent neurons in the cholinergic basal forebrain in AD.

The poor correlation between amyloid load in the brain and the degree of neurological deficits in patients with Alzheimer disease (AD)² (1) or animal models of AD (2, 3) argues against amyloid fibrils being the primary toxic A β species. Recently, soluble A β assemblies, also referred to as A β oligomers (4), protofibrils (5, 6), or A β -derived diffusible ligands (7), have attracted attention because of their potency to impair neuronal function or induce neuritic degeneration (7–13). Several possi-

bilities have been proposed in regard to the toxicities of soluble A β assemblies (e.g. the binding of assemblies to target molecules on neuronal membranes (7, 14) and the ubiquitous disruption of the plasma membrane in association with the perturbation of ionic homeostasis (15)). It is also noteworthy that neurotoxicities induced by soluble A β assemblies are mediated, at least in part, by the activation of signal transduction pathways, including those involving Src family kinases, extracellular signal-regulated kinase, or sphingomyelinases (7, 11, 16, 17). Notably, the level of soluble A β assemblies increases in the brain and cerebrospinal fluid of AD patients (18, 19, 20, 21, 22), and oligomer-specific immunoreactivity is readily observed in the AD brain (23). Furthermore, the inhibition of long term potentiation and the impairment of cognitive function *in vivo* can be induced by natural A β oligomers (9, 24) or a specific A β assembly called A β *56, which has recently been isolated from Tg2576 mice (expressing a human amyloid precursor protein variant-linked familial AD) (25). Additionally, recent studies using AD mouse models revealed that soluble A β assemblies may play a role in the induction of tau pathology (26) and that the genetic deletion of β -secretase, which is responsible for A β production, rescues temporal memory deficit in conjunction with the suppression of the increase in the levels of cerebral A β -derived diffusible ligands (27). These lines of evidence indicate the pathological relevance of these soluble A β assemblies in AD development. However, it remains to be elucidated how these assemblies are formed *in vivo*.

Several mutations within the A β sequence have been reported to be responsible for the development of familial AD and hereditary cerebral amyloid angiopathy (28–32). Among these mutations, the Arctic mutation, unlike other mutations, accelerates the development of clinical and neuropathological features indistinguishable from those of sporadic AD, although it does not increase A β 42 level or A β 42/A β 40 ratio (30). The pathological features induced by the Arctic mutation, including predominant A β deposition in the brain parenchyma, have also been confirmed in transgenic mice (33). Notably, A β bearing the Arctic mutation shows a propensity to form neurotoxic nonamyloid assemblies, including protofibrils, amyloid pores, and small nonfibrillar assemblies (13, 30, 34). Thus, researchers have focused on the Arctic mutation in terms of the mechanisms underlying the formation of soluble and insoluble A β assemblies.

In regard to the assembly of wild-type and hereditary variant-type A β s, we have recently observed that Arctic-type A β , unlike other hereditary variant-type A β s (*i.e.* Dutch-type, Italian-type,

* This study was supported by Grant-in-aid for Scientific Research on Priority Areas 1700220004, Research on Pathomechanisms of Brain Disorders, from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Dept. of Alzheimer's Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, 36-3 Gengo, Morioka, Obu 474-8522, Japan. Tel.: 81-562-44-5651 (ext. 5002); Fax: 81-562-44-6594; E-mail: katsuhiko@nils.go.jp.

² The abbreviations used are: AD, Alzheimer disease; TA β , toxic soluble A β assembly; NGF, nerve growth factor; LDH, lactate dehydrogenase; siRNA, small interfering RNA; AFM, atomic force microscopy; GM1, Gal β 1,3GalNAc β 1,4(Neu5Ac- α 2,3)Gal β 1,4Glc β 1,1-ceramide; ThT, thioflavin-T; NTR, neurotrophin receptor.

and Flemish-type A β s), preferably assembles in the presence of GM1 ganglioside, as does wild-type A β (35, 36). We also reported that GM1 ganglioside level increases in synaptosomes prepared from aged, human apolipoprotein E4 knock-in mice (37). Thus, it is possible that an alteration in the expression or distribution of GM1 ganglioside is the background to the assembly and deposition of A β in the brain parenchyma. This possibility has been supported by findings of recent studies as follows: 1) GM1 ganglioside level increases in membrane microdomains isolated from the frontal cortex but not from the temporal cortex, reflecting earlier and later stages of AD pathology, respectively (38), and 2) GM1 ganglioside level also increases in amyloid-positive nerve terminals obtained from the AD cortex (39).

In this study, we aimed to characterize the toxicity of assemblies formed from Arctic-type A β in the presence of GM1 ganglioside. We found that a toxic soluble A β assembly (TA β) is formed more rapidly and to a greater extent from Arctic-type A β in the presence of GM1 ganglioside than from wild-type A β . Furthermore, our results suggest that TA β induces nerve growth factor (NGF) receptor-mediated neuronal death. Thus, we propose that soluble A β assemblies, such as TA β , are responsible for plaque-independent neuronal death that favorably occurs in NGF-dependent neurons in AD.

MATERIALS AND METHODS

Preparation of Seed-free A β Solutions and Liposomes—Synthetic wild-type A β (A β 40) and Arctic-type A β (A β 40) (Peptide Institute, Osaka, Japan) were dissolved in 0.02% ammonia solution at 500 μ M. To obtain seed-free A β solutions, the prepared solutions were centrifuged at 540,000 $\times g$ for 3 h using an Optima TL ultracentrifuge (Beckman) to remove undissolved peptides that can act as preexisting seeds. The supernatant was collected and stored in aliquots at -80°C until use. Immediately before use, the aliquots were thawed and diluted with Tris-buffered saline (150 mM NaCl and 10 mM Tris-HCl, pH 7.4). To prepare liposomes, cholesterol (Sigma), sphingomyelin (Sigma), and GM1 ganglioside (Matreya LLC) were dissolved in chloroform/methanol at a molar lipid ratio of 50:50:0, 45:45:10, 42.5:42.5:15, or 40:40:20. The mixtures were stored at -80°C until use. Immediately before use, the lipids were resuspended in Tris-buffered saline at a ganglioside concentration of 2.5 mM, and the suspension was subjected to freezing and thawing and sonication.

Cell Culture—Cerebral cortical neurons were prepared from embryonic day 17 Sprague-Dawley rats and cultured in a serum-free medium consisting of Dulbecco's modified Eagle's medium nutrient mixture and N2 supplement. Rat pheochromocytoma PC12 (PC12) cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% heat-inactivated horse serum (Invitrogen) and 5% fetal bovine serum (Invitrogen). For their differentiation, PC12 cells were plated on 2-cm² poly-L-lysine-coated (10 mg/ml) dishes at a density of 20,000 cells/cm² and cultured for 6 days in Dulbecco's modified Eagle's medium supplemented with 100 ng/ml NGF (PC12N) (Alomone Laboratories, Jerusalem, Israel). Human neuroblastoma SH-SY5Y (SY5Y) cells were cultured in Dulbecco's modified Eagle's medium/Ham's F-12 medium supplemented with

10% fetal bovine serum. All of the cells were cultured in humidified 5% CO₂ at 37 $^{\circ}\text{C}$.

A β Incubation in the Presence of GM1 Ganglioside—A seed-free A β solution was incubated at 37 $^{\circ}\text{C}$ and 50 μ M, unless otherwise indicated, in the presence or absence of GM1 ganglioside-containing liposomes, as previously reported (40). The concentration of GM1 ganglioside in the incubation mixtures was 500 μ M, and the molar ratio of GM1 ganglioside in the liposomes varied, as indicated in each figure.

ThT Assay—A β solutions were incubated in the presence of liposomes at 50 μ M and 37 $^{\circ}\text{C}$ for various durations. The ThT fluorescence intensity of the incubation mixtures was determined using a spectrofluorophotometer (RF-5300PC) (Shimadzu Co., Kyoto, Japan). The optimum fluorescence intensity of amyloid fibrils was measured at excitation and emission wavelengths of 446 and 490 nm, respectively, with the reaction mixture (1.0 ml) containing 5 μ M ThT and 50 mM glycine-NaOH at pH 8.5. The fluorescence intensity was measured immediately after preparing the mixture.

LDH Release Assay—The LDH assay was performed on medium using an LDH assay toxicity kit (Promega, Madison, WI). The degree of LDH release in each sample was assessed by measuring absorbance at 490 nm using an Emax precision microplate reader (Molecular Devices Corp., Sunnyvale, CA). Background absorbances, as assessed using cell-free wells, were subtracted from the absorbances of each test sample. Absorbances measured from three wells were averaged, and the percentage degree of LDH release was calculated by dividing the absorbance measured from each test sample following treatment with 1% Triton X-100 to induce the release of intracellular LDH according to instructions provided by the manufacturer.

Electron and Atomic Force Microscopies—For electron microscopy, the samples were diluted with distilled water and spread onto carbon-coated grids. The grids were negatively stained with 2% uranyl acetate and examined under a JEM-2000EX transmission electron microscope (Tokyo, Japan) with an acceleration voltage of 100 kV. Atomic force microscopy (AFM) assessment was performed as described elsewhere (41). Briefly, the samples were dropped onto a freshly cleaved mica. After leaving them to stand for 3 min and then washing with water, the samples were assessed in a solution using a Nanoscope IIIa (Digital Instruments, Santa Barbara, CA) set in the tapping mode (42). OMCL-TR400PSA (Olympus, Japan) was used as a cantilever. The resonant frequency was ~ 9 kHz.

Size Exclusion Chromatography—The molecular mass of TA β was determined using a Superose 12 size exclusion column (1 \times 30 cm; GE Healthcare) equilibrated with phosphate-buffered saline (pH 7.4) at a flow rate of 0.5 ml/min. Thirty-five fractions were collected and analyzed by dot blotting using anti-Oligo.

Preparation of Synaptosomes—Synaptosomes were prepared as previously described (43). A hippocampus or a whole brain minus the hippocampus was homogenized in 0.32 M sucrose buffer containing 0.25 mM EDTA. The homogenate was centrifuged at 580 $\times g$ for 8 min. The supernatant was centrifuged at 145,000 $\times g$ for 20 min. The resulting pellet was suspended in 0.32 M sucrose buffer without EDTA and layered over Ficoll in sucrose buffer. Following centrifugation at 87,000 $\times g$ for 30